Brain Cancer Trial, Recruiting NCT06231186 Sponsor: Ruijin Hospital Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT06231186
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the research, are willing to take part, and can sign a consent form
  • People with a general health status rated as reasonably functional (on a standard scale used by doctors to measure how well a person can carry out daily activities — confirm with trial site)
  • People whose cancer (either at the original site or a site where it has spread) has been confirmed by a tissue sample taken from a biopsy or surgery
  • People who have brain metastases (cancer that has spread to the brain) confirmed by an MRI scan, with measurable tumours that are suitable for a targeted form of radiation treatment called stereotactic radiotherapy — with no more than 15 separate tumour spots and no single tumour larger than 20cc in volume
  • People whose doctors estimate they are likely to live for at least 3 more months

Who may not be able to join:

  • People whose cancer has spread widely and diffusely throughout the brain, or whose cancer has spread to the lining around the brain (meninges), or for whom the targeted radiotherapy treatment would not be technically possible
  • People who have serious other health conditions or medical reasons that mean radiotherapy cannot safely be given
  • People whom the trial team considers unsuitable for other reasons, such as concerns about whether they would be able to follow the trial's requirements

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Jiayi Chen, Ruijin Hospital

Phone: 8618801970632

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
15 March 2024
Est. completion
1 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

proportion of patients receiving BED 10 >50 Gy; the incidence of radiation-induced brain necrosis

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov